Comparative Pharmacology
Head-to-head clinical analysis: COREG CR versus INDERAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COREG CR versus INDERAL.
COREG CR vs INDERAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Nonselective beta-adrenergic receptor antagonist; competes with catecholamines for binding at beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
Hypertension: 40 mg orally twice daily; increase as needed up to 640 mg/day. Angina: 80-320 mg orally daily in divided doses. Migraine prophylaxis: 80 mg orally daily in divided doses; up to 160-240 mg/day. Arrhythmias: 10-30 mg orally 3-4 times daily. IV: 1-3 mg IV bolus at 1 mg/min; may repeat after 2 min.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
3-6 hours (terminal). Clinical context: half-life increases with chronic dosing due to saturable hepatic metabolism; in cirrhosis, half-life may be prolonged to 10-23 hours.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Renal: 96-99% as metabolites (active 4-hydroxypropranolol and conjugates), <1% unchanged. Biliary/fecal: minimal.
Category C
Category C
Beta-Blocker
Beta-Blocker